Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study

Journal of Urology

Volumn 182, Issue 6, 2009, Pages 2831-2835

  Matsukawa, Yoshihisa ^a   Gotoh, Momokazu ^a   Komatsu, Tomonori ^a   Funahashi, Yasuhito ^a   Sassa, Naoto ^a   Hattori, Ryohei ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

adrenergic antagonists; KMD 3213; prostatic hyperplasia; urinary bladder neck obstruction; urodynamics

Indexed keywords

SILODOSIN;

ADULT; AGED; ARTICLE; BLADDER CAPACITY; BLADDER FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOMETRY; DETRUSOR MUSCLE; DRUG EFFICACY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MICTURITION; NOMOGRAM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RESIDUAL URINE; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT OBSTRUCTION; URINE FLOW RATE; UROFLOWMETRY;

AGED; AGED, 80 AND OVER; HUMANS; INDOLES; MALE; MIDDLE AGED; PRESSURE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; PROSTATISM; URINARY BLADDER NECK OBSTRUCTION; URODYNAMICS;

EID: 71849107978     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.08.030     Document Type: Article

References (27)

1. Shapiro E., Becich M.J., Hartanto V., et al. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 147 (1992) 1293
2. American Urological Association guideline on management of benign prostatic hyperplasia (2003). Chapter1: diagnosis and treatment recommendations. J Urol 170 (2003) 530
3. Schwinn D.A., and Roehrborn C.G. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 15 (2008) 193
4. Andersson K.F. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 19 (2002) 390
5. Malloy B.J., Price D.T., Price R.R., et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 160 (1998) 937
6. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic. hyperplasia. Urology 51 (1998) 892
7. Gotoh M., Kamihira O., Kinukawa T., et al. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 96 (2005) 581
8. Cooper K.L., McKiernan J.M., and Kaplan S.A. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 57 (1999) 9
9. Martorana G., Giberti C., Di Silverio F., et al. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Eur Urol 32 (1997) 47
10. Abrams P., Speakman M., Stott M., et al. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80 (1997) 587
11. Ozbey I., Aksoy Y., Polat O., et al. Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment. Int Urol Nephrol 31 (1999) 471
12. Shibata K., Foglar R., Horie K., et al. KMD-3213, a novel, potent, α1A adrenoceptor-selective antagonist: characterization using recombinant human α1-adrenoceptors and native tissues. Mol Pharmacol 48 (1995) 250
13. Kawabe K., Yoshida M., and Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98 (2006) 1019
14. Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficacy: three simple indices to define bladder voiding function. BJU Int 84 (1999) 14
15. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology 61 (2003) 37
16. Nasu K., Moriyama N., Fukasawa R., et al. Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol 123 (1998) 1289
17. Takao T., Tsujimura A., Kiuchi H., et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol 15 (2008) 992
18. Tatemichi S., Akiyama K., Kobayashi M., et al. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 176 (2006) 1236
19. Elhilali M.M., Ramsey E.W., Barkin J., et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 47 (1996) 335
20. Yamanishi T., Yasuda K., Kamai T., et al. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Int J Urol 11 (2004) 501
21. Hampel C., Dolber P.C., Smith M.P., et al. Modulation of bladder α1 adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 167 (2002) 1513
22. Smith M.S., Schambra U.B., Wilson K.H., et al. Alpha 1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha 1-adrenergic subtypes at four distinct levels. Brain Res Mol Brain Res 63 (1999) 254
23. Persson K., Pandita R.K., Spitsbergen J.M., et al. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 275 (1998) 1366
24. Chen Q., Takahashi S., Zhong S., et al. Function of the lower urinary tract in mice lacking alpha 1d-adrenoceptor. J Urol 174 (2005) 370
25. Ishihama H., Momota Y., Yanase H., et al. Activation of alpha 1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol 175 (2006) 358
26. Nomiya M., and Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenergic subtypes and their functional roles in human normal and obstructed bladders. J Urol 170 (2003) 649
27. Yokoyama O., Nagano K., Kawaguchi K., et al. The influence of prostatic urethral anesthesia in overactive detrusor in patients with benign prostatic hyperplasia. J Urol 151 (1994) 1554